Company news

Viking Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Viking Therapeutics to Present at SVB Leerink 11th Annual Global Healthcare Conference

February 6, 2022

Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2021 on February 9, 2022

February 1, 2022

Viking Therapeutics Announces Clinical Hold on Phase 1b Trial of VK0214 in Patients with X-ALD

January 23, 2022

Viking Therapeutics Announces Initiation of Phase 1 Clinical Trial of VK2735, Company's Lead Dual GLP-1/GIP Receptor Agonist

January 9, 2022

Viking Therapeutics to Present at H.C. Wainwright BioConnect 2022 Conference

January 2, 2022

Viking Therapeutics to Present at Stifel 2021 Virtual Healthcare Conference

November 8, 2021

Viking Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

November 2, 2021

Viking Therapeutics Presents Preclinical Data on Novel Dual GLP-1/GIP Agonists at ObesityWeek® 2021

October 31, 2021

Viking Therapeutics to Report Financial Results for Third Quarter 2021 on November 3, 2021

October 26, 2021

Viking Therapeutics to Present Preclinical Data on Novel Dual GLP-1/GIP Agonists at ObesityWeek 2021

October 24, 2021

Viking Therapeutics to Present at H.C. Wainwright's 5th Annual NASH Investor Conference

October 4, 2021

Viking Therapeutics to Participate in Upcoming Investor Conferences

September 1, 2021

Viking Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update

July 27, 2021

Viking Therapeutics to Report Financial Results for Second Quarter 2021 on July 28, 2021

July 20, 2021

Viking Therapeutics Announces Initiation of Phase 1b Clinical Trial of VK0214 in Patients with X-ALD

June 23, 2021

Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Novel Oral Thyroid Receptor Beta Agonist VK0214

June 16, 2021

Viking Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

April 27, 2021

Viking Therapeutics to Report Financial Results for First Quarter 2021 on April 28, 2021

April 20, 2021

Viking Therapeutics to Present at 20th Annual Needham Virtual Healthcare Conference

April 6, 2021

Viking Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update

February 16, 2021

Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2020 on February 17, 2021

February 9, 2021

Viking Therapeutics Announces Senior Management Team Appointments

January 5, 2021

Viking Therapeutics to Present at H.C. Wainwright BioConnect 2021 Conference

January 4, 2021

Viking Therapeutics to Present at Stifel Healthcare Conference 2020

November 9, 2020

Viking Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update

October 27, 2020

Viking Therapeutics to Report Financial Results for Third Quarter 2020 on October 28, 2020

October 20, 2020

Viking Therapeutics Announces Initiation of Phase 1 Clinical Trial of VK0214

September 8, 2020

Viking Therapeutics Presents New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The Digital International Liver Congress™ 2020

August 27, 2020

Viking Therapeutics to Present New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The Digital International Liver Congress™ 2020

August 19, 2020

Viking Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update

July 28, 2020

Viking Therapeutics to Report Financial Results for Second Quarter 2020 on July 29, 2020

July 21, 2020

Viking Therapeutics Announces 2020 Annual Meeting of Stockholders to be Held as Virtual Meeting

May 11, 2020

Viking Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

April 29, 2020

Viking Therapeutics to Report Financial Results for First Quarter 2020 on April 30, 2020

April 22, 2020

Viking Therapeutics to Participate in 19th Annual Needham Healthcare Conference

April 6, 2020

Viking Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Corporate Update

February 25, 2020

Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2019 on February 26, 2020

February 18, 2020

Viking Therapeutics to Present at Biotech Showcase 2020

January 5, 2020

Viking Therapeutics Announces Initiation of Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)

November 18, 2019

Viking Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

November 4, 2019

Viking Therapeutics to Report Financial Results for Third Quarter 2019 on November 5, 2019

October 30, 2019

Viking Therapeutics to Present at 2019 Cantor Global Healthcare Conference

September 24, 2019

Viking Therapeutics to Report Financial Results for Second Quarter 2019 on August 1, 2019

July 24, 2019

Viking Therapeutics Appoints Kathy Rouan, Ph.D., to Board of Directors

July 1, 2019

Viking Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update

May 1, 2019

Viking Therapeutics to Report Financial Results for First Quarter 2019 on May 2, 2019

April 24, 2019

Viking Therapeutics Presents New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The International Liver Congress(TM) 2019

April 10, 2019

Viking Therapeutics to Present New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The International Liver Congress(TM) 2019

April 3, 2019

← Newer news releases

Calls

The 5 newest of 19 calls. Every call is listed under its year.

Decks

The 5 newest of 7 decks. Every deck is listed under its year.